Insights into Mycobacterium Evolution from a Leprosy Vaccine
Author Information
Author(s): Ahmed Niyaz, Saini Vikram, Raghuvanshi Saurabh, Khurana Jitendra P., Tyagi Akhilesh K., Tyagi Anil K., Hasnain Seyed E.
Primary Institution: Centre for DNA Fingerprinting and Diagnostics (CDFD), Hyderabad, India
Hypothesis
How did Mycobacterium indicus pranii evolve and what are its immunomodulating properties?
Conclusion
The study suggests that Mycobacterium indicus pranii is a predecessor of pathogenic mycobacteria and has unique immunomodulating properties.
Supporting Evidence
- Mycobacterium indicus pranii has shown enhanced bacillary clearance in leprosy patients.
- It shares antigens with both M. leprae and M. tuberculosis.
- MIP is currently undergoing advanced clinical trials for its efficacy against tuberculosis.
Takeaway
Researchers studied a type of bacteria used in leprosy vaccines to understand how it evolved and helps the immune system fight diseases.
Methodology
The study used genome-wide comparisons and molecular phylogenetic analyses to investigate the evolutionary history of Mycobacterium indicus pranii.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website